New hope for rare bile duct cancer: targeted pill may prevent return

NCT ID NCT07260175

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 16, 2026 · Updated 25 times

Summary

This study tests whether a daily pill called ivosidenib can help keep bile duct cancer from returning after surgery and chemotherapy. It is for people with a specific gene change (IDH1 mutation). About 40 adults will take the drug for one year, and researchers will track how many remain cancer-free after that time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Klinikum rechts der Isar TU München
RECRUITING

München, 81675, Germany

Contact
Krankenhaus Nordwest
RECRUITING

Frankfurt, 60488, Germany

Contact
Uniklinik RWTH Aachen
RECRUITING

Aachen, 52074, Germany

Contact
Uniklinikum Jena
RECRUITING

Jena, 7747, Germany

Contact
Universitätsklinikum Bonn
RECRUITING

Bonn, 53127, Germany

Contact
Universitätsklinikum Frankfurt
RECRUITING

Frankfurt, 60590, Germany

Contact
Universitätsklinikum Mannheim
RECRUITING

Mannheim, 68167, Germany

Contact
Universitätsmedizin Göttingen
RECRUITING

Göttingen, 37099, Germany

Contact

Conditions

Explore the condition pages connected to this study.

CHOLANGIOCARCINOMA IDH MUTATION IDH MUTATION